What if you could access quality healthcare with just a tap on your phone—and invest in the company making it happen? Welcome to the world of Hims & Hers Health, Inc., a trailblazer in the telehealth industry that’s redefining how we approach wellness. As telehealth adoption skyrockets in 2025, Hims stock has become a hot topic for investors eager to tap into this booming sector. But is it the right opportunity for you?
In this 2000+ word guide, we’ll break down everything you need to know about Hims stock—from the company’s innovative business model and financial performance to its market position and future prospects. Whether you’re weighing telehealth stocks for your portfolio or curious about the Hims & Hers stock price, this article delivers actionable insights to help you decide. Let’s dive in!
Table of Contents
What is Hims & Hers?
Hims & Hers Health, Inc. is a telehealth platform that’s shaking up traditional healthcare. Launched in 2017, Hims first targeted men’s health, offering solutions for erectile dysfunction, hair loss, and skincare. In 2019, it expanded with the Hers brand, adding women’s health services like birth control, sexual health, and mental wellness. Today, Hims provides a broad range of care, including primary care and dermatology, all accessible online.
How It Works
Hims connects patients with licensed healthcare providers through virtual consultations. Here’s the process:
- Online Assessment: Patients fill out a questionnaire about their health needs.
- Consultation: A provider reviews the case and offers a personalized treatment plan.
- Delivery: Prescriptions and products are shipped discreetly to your door.
Hims also offers subscriptions for ongoing care, appealing to those seeking convenience and consistency.
Who’s It For?
Hims targets millennials and Gen Z—tech-savvy generations that prioritize accessibility and privacy. With a sleek, modern brand and a judgment-free approach to sensitive health topics, Hims stands out from old-school healthcare providers.
Financial Performance of Hims Stock
Understanding Hims stock starts with its financials. Since going public in 2021 via a SPAC merger, Hims has shown robust growth, though profitability remains a work in progress.
Revenue Growth
Hims’ revenue has soared in recent years:
- 2022: $527 million
- 2023: $872 million (65% increase)
- 2024: $1.2 billion (38% increase)
This growth stems from expanding its customer base, boosting order values, and adding new services like mental health support.
Profitability
Hims is still investing heavily in growth, so losses are part of the picture:
- 2022: Net loss of $108 million
- 2023: Net loss of $65 million
- 2024: Net loss of $30 million
However, 2024 marked a milestone with positive adjusted EBITDA, hinting at profitability ahead.
Key Metrics
| Metric | Value |
|---|---|
| Gross Margin | 82% |
| Revenue Growth | 38% |
| Customer Acquisition Cost (CAC) | Decreasing |
| Lifetime Value (LTV) | Increasing |
Stock Price Trends
As of mid-2025, Hims & Hers stock price hovers around $18, down from a 2022 peak of $25 but up from its $10 debut. Volatility is common in telehealth stocks, so expect ups and downs.
Market Trends in Telehealth
The telehealth industry is booming, and Hims is riding the wave. Per Grand View Research, the global telehealth market hit $79.8 billion in 2022 and is projected to grow at a 25.2% CAGR through 2030.
Why Telehealth Is Growing
- Convenience: Care from home beats waiting rooms.
- Cost Savings: Virtual visits often cost less.
- Pandemic Push: COVID-19 normalized remote healthcare.
- Tech Advances: Better tools enhance the experience.
Hims capitalizes on these trends with its user-focused platform and subscription model.
Competitive Landscape
Hims isn’t alone in telehealth. Here’s how it stacks up:
Key Competitors
- Teladoc Health: A giant with a wide service range.
- Amwell: Known for broad virtual care options.
- Ro: A direct rival focusing on similar niches.
Hims’ Edge
Hims shines with its branding and niche focus. Unlike Teladoc’s broad approach, Hims hones in on specific needs—think sexual health or skincare—delivering a tailored experience.
Challenges
Bigger players like Teladoc have deeper insurance ties, which Hims lacks. Staying competitive means expanding services and retaining customers.
Investment Considerations for Hims Stock
Is investing in Hims right for you? Let’s weigh the factors.
Valuation
Hims’ price-to-sales ratio is ~3.5 in 2025, competitive among telehealth peers. Without consistent profits, its P/E ratio isn’t yet meaningful.
Growth Potential
Hims has room to grow by:
- Expanding internationally.
- Adding services like chronic care.
- Partnering with insurers.
Risks
- Regulation: Changes in telehealth laws could disrupt operations.
- Competition: New entrants might steal market share.
- Economy: Downturns could cut discretionary spending.
Analyst Views
Analysts are split—some see Hims as a growth gem, others worry about profitability delays.
What’s New in 2025 for Hims?
In 2025, Hims rolled out personalized mental health plans and expanded its primary care offerings. Rumors of a European launch are also swirling, which could boost Hims stock if confirmed.
Frequently Asked Questions (FAQs)
1. What is Hims & Hers’ business model?
Hims & Hers delivers telehealth services via an online platform, connecting patients with providers for virtual care. Founded in 2017, it started with men’s health—think hair loss and ED treatments—before adding women’s health in 2019. Now, it covers mental health, dermatology, and more.
Patients start with an online form, consult a provider, and get prescriptions or products delivered. Subscriptions keep care ongoing and affordable. Hims skips traditional healthcare middlemen, cutting costs and boosting accessibility. Revenue comes from consultations, product sales, and subscriptions.
This model resonates with younger adults who value convenience and privacy. Hims’ branding—modern and approachable—sets it apart, making healthcare feel less clinical and more relatable.
2. How has Hims stock performed historically?
Since its 2021 SPAC debut at $10, Hims stock has been a rollercoaster. It hit $25 in 2022 amid telehealth hype but dropped as growth stocks cooled. By mid-2025, it’s around $18, reflecting both promise and uncertainty.
Revenue growth drives optimism—$527 million in 2022 to $1.2 billion in 2024—but losses ($108 million to $30 million) temper gains. Volatility ties to market trends and telehealth sentiment. Past performance isn’t a crystal ball, so focus on Hims’ fundamentals for future bets.
3. What are the growth prospects for Hims?
Hims’ growth looks promising. It can scale its U.S. base, go global, and add services like chronic care or pediatrics. The telehealth market’s 25%+ CAGR supports this, and Hims’ subscription model ensures steady revenue.
International expansion is a big “if”—success abroad could spike Hims stock. Partnerships with insurers or employers could also unlock new customers. Innovation will be key to staying ahead.
4. What are the risks of investing in Hims stock?
Investing in Hims isn’t risk-free. Regulatory shifts—like stricter telehealth rules—could hit operations. Competition from Teladoc or Ro might squeeze margins. High marketing costs, even if dropping, challenge profitability. Economic dips could also reduce spending on Hims’ services.
Diversify and research to mitigate these risks. Watch quarterly reports for updates.
5. How does Hims compare to other telehealth companies?
Hims focuses on niche areas—sexual health, mental wellness—unlike Teladoc’s broad scope. Ro mirrors Hims’ model but lacks its brand clout. Amwell offers versatility but less consumer appeal. Hims’ subscription edge drives loyalty, though bigger rivals have insurance advantages.
6. Is Hims a good investment for long-term growth?
Hims offers growth potential with its 38% revenue jump in 2024 and telehealth’s rise. Positive EBITDA is a green flag, but losses and risks—like regulation—loom. If you’re risk-tolerant and believe in telehealth, Hims could shine long-term. Assess your goals first.
Conclusion
Hims stock blends opportunity and uncertainty in the telehealth boom. With strong growth, a loyal base, and a 2025 expansion push, Hims is a contender. Yet, profitability and competition remain hurdles. Whether you’re eyeing telehealth stocks or researching Hims & Hers stock price, this guide offers the tools to decide.
